Quantisnow Logo
Dashboard

SEC Form 15-12G filed by Sio Gene Therapies Inc.

$SIOX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $SIOX alert in real time by email
15-12G 1 siox15-12g04142023.htm 15-12G Document



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-37418
Sio Gene Therapies Inc.
(Exact name of registrant as specified in its charter)
1501 Broadway, 12th Floor
New York, NY 10036
(646) 677-6770
(Address, including zip code, and telephone number,
including area code, of registrant’s principal executive offices)
Common Stock, $0.00001 par value
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which
a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)
☒
Rule 12g-4(a)(2)
☐
Rule 12h-3(b)(1)(i)
☒
Rule 12h-3(b)(1)(ii)
☐
Rule 15d-6
☐
Rule 15d-22(b)
☐

Approximate number of holders of record as of the certification or notice date: 4.




    Pursuant to the requirements of the Securities Exchange Act of 1934, Sio Gene Therapies Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

SIO GENE THERAPIES INC.
Dated:
April 25, 2023
By:
/s/ David Nassif
Name:
David Nassif
Title:
Chief Executive Officer; Chief Financial Officer; Chief Accounting Officer; and General Counsel
Get the next $SIOX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SIOX

DatePrice TargetRatingAnalyst
2/1/2022$10.00 → $7.00Buy
HC Wainwright & Co.
2/1/2022$6.00 → $1.00Outperform → Market Perform
SVB Leerink
10/21/2021$8.00 → $10.00Buy
HC Wainwright & Co.
8/12/2021$7.00 → $6.00Outperform
SVB Leerink
7/12/2021$12.50Buy
Chardan Capital Markets
More analyst ratings

$SIOX
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share

    PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of the State of Delaware, as contemplated by the Plan of Complete Liquidation and Dissolution (the "Plan") previously approved by Sio's Board of Directors and stockholders, on February 7, 2024. The Certificate of Dissolution, which is expected to become effective at 4:00 p.m. Eastern Time on February 7, 2024 (the "Effective Time"), provides for the dissolution of Sio under the General Corporation Law of the State of Delaware (the "DGCL"). In connection with the filing of th

    $SIOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

    –  Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively –  Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period –  $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022. "Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination

    $SIOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution

    NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries. "After evaluating the Company's strategic options, the Board of Directors unanimously concluded that it is in the best interests of the shareholders to dissolve and liquidate the Company," stated David Nassif, Chief Executive Officer. "The Board of Directors and management, together with its external advisors, devoted substanti

    $SIOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SIOX
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SIOX
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SIOX
 SEC Filings

See more

$SIOX
 Financials

Live finance-specific insights

See more

  • Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis

    Consistent dose-dependent improvements across biomarker measuresNormalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and high-dose cohorts Total of ten patients have received gene therapy to date without SAEs attributable to AXO-AAV-GM1 Management to host conference call and webcast today, October 21, at 8:30 a.m. EDT NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today pres

    $SIOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Sio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31, 2020

    - Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided financial results for its third fiscal quarter ended December 31, 2020. “In recent months, Sio Gene Therapies has made important progress in advancing its patient-fo

    $SIOX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SIOX
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more